OneSource Speci.
OneSource Specialty Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Get OneSource Speci.'s next results in your feed
Guidance rank: #3 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards. FY '26 is a transitory year with focus on building operating capacity and scale readiness.
From OneSource Speci.'s Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards.
- FY '28 guidance reiterated with confidence to become a ₹400 crore revenue company organically.
- Customer orders strengthening with an expanding product pipeline, including drug-device combinations and biologics.
- Capacity expansion capex of over ₹700 crore progressing well; significant additional capacities expected by H2 FY '27.
- Customer forecasts are being revised upward consistently, indicating growing demand.
- Sequential quarter-on-quarter improvement anticipated starting FY '27 as approvals materialize.
- Biologics CDMO business showing strong growth with RFPs almost 4x of previous levels and new major biosimilar customers onboarded.
2 more points from OneSource Speci.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what OneSource Speci. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site expansion, particularly in the DDC (Drug Device Combination) business.
- By end of FY27, installed new capacities worth around $200 million are expected, with incremental capacity enhancements happening throughout the year.
- Investments include building microbial capacity for biologics CDMO, considered unique and competitive.
- Capex plans also cover expansion in lyophilization and new capabilities at the general injectables site in Bangalore.
- Around three-quarters of the planned $100 million capex for the flagship site have already been committed.
2 more points from OneSource Speci.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Speci. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- OneSource has strong visibility from customers, including long-term commitments extending beyond three years.
- They prioritize commercial sales over MSAs (Manufacturing Service Agreements) to optimize capacity utilization and economics.
- Customer orders continue to strengthen despite near-term approval delays.
- Customer forecasts are being revised upwards consistently, reflecting confidence in future demand.
- The company has been renegotiating take-or-pay contracts to secure more structured, longer-term relationships.
- Inventory build-up for significant upcoming semaglutide launches is customer-backed with advances or firm purchase orders.
2 more points from OneSource Speci.'s call on order book
Create a free account to keep reading this call
OneSource Speci. — Quarterly revenue & net profit
OneSource Speci. Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 290 | 393 | -26.2% | 376 | -22.9% |
| Operating profit (EBITDA) | 17 | 142 | -88% | 106 | -84% |
| Operating margin | 6% | 36% | -30 pp | 28% | -22 pp |
| Profit before tax | -93 | -67 | — | 6 | -1650% |
| Net profit (PAT) | -89 | -69 | — | 10 | -990% |
| EPS (₹) | -7.74 | -6.02 | — | 0.92 | -941.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹516 Cr, net profit ₹57 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Specialty Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
OneSource Speci. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Speci. Q3 FY26 results?
Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards. FY '26 is a transitory year with focus on building operating capacity and scale readiness.
What is OneSource Speci. share price analysis?
OneSource Speci. currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,602 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Speci. planning capital expenditure?
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site expansion, particularly in the DDC (Drug Device Combination) business.
Keep OneSource Speci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.